📊 IRME Key Takeaways
Is IRME a Good Investment? Thesis Analysis
IR-Med is a distressed medical device company with severe structural insolvency, negative stockholders' equity of -$625K, and catastrophic revenue collapse of -115% YoY alongside -$1.5M net losses. The company is cash flow negative with operating cash burn of -$181K, critically low liquidity (0.12x current ratio), and minimal cash reserves ($63K) that cannot sustain operations or service $800K in liabilities.
Why Buy IRME? Key Strengths
- Minimal capital expenditure requirements suggest low ongoing infrastructure costs
- Some operational focus in medical device sector with regulatory barriers to entry
IRME Investment Risks to Consider
- Negative stockholders' equity indicates technical insolvency with liabilities exceeding assets by $625K
- Revenue essentially eliminated (-115% YoY) with only -$3K revenue in latest period indicating operational collapse
- Severe liquidity crisis with current ratio of 0.12x and only $63K cash against $800K total liabilities
- Persistent net losses of -$1.5M with negative operating cash flow of -$181K unsustainable without external capital injection
- Zero insider trading activity in 90 days suggests management has abandoned ship
Key Metrics to Watch
- Cash balance trajectory and runway
- Ability to reverse revenue decline or achieve strategic acquisition/recapitalization
- Quarterly burn rate and path to liquidity event or bankruptcy filing
- Debt restructuring or equity raise announcements
IRME Financial Metrics
💡 AI Analyst Insight
The 6,100.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
IRME Profitability Ratios
IRME vs Healthcare Sector
How IR-Med, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IRME Overvalued or Undervalued?
Based on fundamental analysis, IR-Med, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IRME Balance Sheet & Liquidity
IRME 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: IR-Med, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.07 indicates the company is currently unprofitable.
IRME Growth Metrics (YoY)
IRME Capital Allocation
IRME SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for IR-Med, Inc. (CIK: 0001839133)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IRME
What is the AI rating for IRME?
IR-Med, Inc. (IRME) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRME's key strengths?
Claude: Minimal capital expenditure requirements suggest low ongoing infrastructure costs. Some operational focus in medical device sector with regulatory barriers to entry.
What are the risks of investing in IRME?
Claude: Negative stockholders' equity indicates technical insolvency with liabilities exceeding assets by $625K. Revenue essentially eliminated (-115% YoY) with only -$3K revenue in latest period indicating operational collapse.
What is IRME's revenue and growth?
IR-Med, Inc. reported revenue of $-3.0K.
Does IRME pay dividends?
IR-Med, Inc. does not currently pay dividends.
Where can I find IRME SEC filings?
Official SEC filings for IR-Med, Inc. (CIK: 0001839133) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRME's EPS?
IR-Med, Inc. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IRME a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, IR-Med, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IRME stock overvalued or undervalued?
Valuation metrics for IRME: ROE of N/A (sector avg: 15%), net margin of 49,133.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IRME stock in 2026?
Our dual AI analysis gives IR-Med, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is IRME's free cash flow?
IR-Med, Inc.'s operating cash flow is $-181.0K, with capital expenditures of $2.0K. FCF margin is 6,100.0%.
How does IRME compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 49,133.3% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.12 (avg: 2).